Gamma-aminobutyric acid type A receptor benzodiazepine binding site (GABA-A receptor BZD site) (GABA-A receptor BZD site)

The benzodiazepine binding site is a high-affinity allosteric site located on the Gamma-aminobutyric acid type A (GABA-A) receptor, primarily at the interface of the alpha (α1, α2, α3, or α5) and gamma (γ2) subunits (StatPearls, PMID: 30247833). GABA-A receptors are pentameric ligand-gated ion channels that serve as the primary mediators of rapid inhibitory neurotransmission in the mammalian central nervous system (IUPHAR/BPS Guide to Pharmacology). Binding of benzodiazepines to this site does not activate the receptor directly but instead enhances the receptor's response to the endogenous neurotransmitter GABA by increasing the frequency of chloride channel opening (PubMed, PMID: 22303015). This mechanism results in neuronal hyperpolarization and decreased neuronal firing, which manifests clinically as anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant properties (StatPearls, PMID: 29083758). This site is a critical pharmacological target for a wide range of neuropsychiatric conditions, including generalized anxiety disorder, insomnia, and status epilepticus. However, chronic modulation of this site is associated with significant clinical challenges, including the development of tolerance, physical dependence, and potential for abuse (NIH, MedlinePlus).

Other names

Benzodiazepine receptorBZD siteGABA-A receptor gamma subunit complexOmega receptorBZ siteBenzodiazepine binding site

Positive allosteric modulation of the GABA-A receptor, which increases the frequency of chloride channel opening in response to GABA binding, leading to enhanced inhibitory postsynaptic potentials (StatPearls, PMID: 30247833).